ADVFN - Advanced Financial Network.
HOME» NYSE » V » VRX Stock Price » VRX Stock News

Valeant Pharma Share News

 Valeant Pharmaceuticals International Stock Price
VRX Stock Price
 Valeant Pharmaceuticals International Stock Chart
VRX Stock Chart
 Valeant Pharmaceuticals International Stock News
VRX Stock News
 Valeant Pharmaceuticals International Company Information
VRX Company Information
 Valeant Pharmaceuticals International Stock Trades
VRX Stock Trades

Valeant To Buy Branded Generics Assets From Gerot Lannach

DOW JONES NEWSWIRES Valeant Pharmaceuticals International Inc. (VRX) said Tuesday it's acquiring from Austria's Gerot Lannach certain branded generics assets that generate the bulk of their sales in Russia. Mississauga, Ont.-based Valeant said the assets generated net revenue of about $55 million last year. Gerot Lannach's largest product is acetylsalicylic acid, a low-dose aspirin. Valeant said it will pay less than three times sales, and may make up to an additional $20 million in milestone payments, based upon future performance objectives. As part of the transaction, Valeant and Gerot Lannach will enter into a strategic partnership that includes an exclusive 10-year supply agreement for the acquired products and the opportunity for Valeant to introduce additional Gerot Lannach products into Valeant territories such as its emerging markets in Southeast Asia and Latin America. Valeant expects the transaction to boost results starting immediately. -By Carolyn King, Dow Jones Newswires; 416-306-2100; carolyn.m.king@dowjones.com

Stock News for Valeant Pharma (VRX)
DateTimeHeadline
11/25/201419:25:05Jefferies Bumps Up Against Big Rivals as It Looks to Expand
11/25/201418:53:14CEOs' Test: Contending With Activist Investors
11/20/201412:41:11Valeant Sets $2 Billion Buyback Plan After Losing Allergan
11/19/201419:15:16For Allergan Suitors, Unorthodox Alliance Proved Unwieldy
11/18/201419:55:17Goldman Hits Mother Lode on Deals
11/18/201418:50:13Ackman Drops Push for Allergan Holder Meeting--2nd Update
11/18/201418:40:32Ackman Drops Push for Allergan Holder Meeting--Update
11/18/201408:07:30Zoetis Unveils $500 Million Buyback Plan
11/17/201420:01:10Deal Boom Feeds on Surging Stocks
11/17/201418:16:19Actavis To Buy Allergan In $66 Billion Deal--5th Update
11/17/201416:28:40Actavis To Buy Allergan in $66 Billion Deal -- 5th Update
11/17/201415:35:37Ackman, Valeant Can't Justify Topping Actavis Bid for Allergan
11/17/201410:16:39Actavis To Buy Allergan In $66 Billion Deal--4th Update
11/17/201410:07:59Actavis To Buy Allergan In $66 Billion Deal--3rd Update
11/17/201410:01:21Actavis To Buy Allergan In $66 Billion Deal--2nd Update
11/17/201409:52:21Actavis To Buy Allergan In $66 Billion Deal--Update
11/17/201409:29:21MARKET SNAPSHOT: U.S. Stocks: Futures Lower; Industrial Production...
11/17/201408:07:11MARKET SNAPSHOT: U.S. Stocks: Futures Lower After Japan Falls...
11/17/201402:57:05Valeant Buys Nicox's Ophtalmic Diagnostics for Up to $20 Million
11/16/201419:54:13Allergan, Actavis Near Deal -- 3rd Update

Valeant Pharma and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad